Mouse Tnf ASO
Mouse Tnf ASO is an antisense oligonucleotide (ASO) that targets the expression of mouse TNF-α. Mouse Tnf ASO reduces the tissue levels of various pro-inflammatory cytokines, Th1 cytokines and Th17 cytokines. Mouse Tnf ASO improves the clinical and histopathological severity of experimental colitis, including alleviating weight loss, diarrhea and intestinal protein loss. Mouse Tnf ASO can be delivered to activated colonic macrophages in mice via galactosylated low-molecular-weight chitosan nanocomplexes, with higher delivery efficiency compared to naked ASO. Mouse Tnf ASO can be used in the research of Crohn's disease.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Mouse Tnf ASO can be delivered into mouse peritoneal macrophages via the gal-LMWC/ASO complex (incubated for 1 h), with higher efficiency than naked Mouse Tnf ASO; through an MGL-mediated mechanism, the uptake level of this complex is enhanced in LPS-prestimulated activated macrophages[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
The gal-LMWC/Mouse Tnf ASO complex (5 mg/kg; i.c.; weekly; 5 doses) reduces colonic TNF-α levels by >75% and ameliorates disease symptoms in mice with CD4+CD45RBhi T cell-mediated chronic colitis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c mice (6- to 8-week-old female; TNBS-induced acute colitis)[1]
-
Dosage:0.2 mg/kg, 1.0 mg/kg, 5.0 mg/kg, 20.0 mg/kg
-
Administration:i.c.; single administration
-
Result:Reduced colonic TNF-α protein levels in a dose-dependent manner, with significant decreases at 5.0 and 20.0 mg/kg compared to untreated colitis mice.
Reduced colonic TNF-α mRNA and protein levels by >85% at 5 mg/kg.
Reduced colonic levels of proinflammatory (IL-1β, IL-6), Th1 (IFN-γ, IL-12), and Th17 (IL-17, IL-23) cytokines at 5 mg/kg.
Normalized body weight at 5 mg/kg.
Reduced disease activity index (DAI) scores at 5 mg/kg.
Achieved 100% survival (vs. 40% survival in untreated colitis mice) at 5 mg/kg.
Eliminated macroscopic colonic inflammation at 5 mg/kg.
Reduced colonic myeloperoxidase (MPO) activity to near-normal levels at 5 mg/kg.
Normalized faecal α1-antitrypsin (AAT) levels at 5 mg/kg.
Significantly improved histopathological scores at 5 mg/kg.
-
Animal Model:BALB/c severe combined immunodeficiency (SCID) mice (reconstituted with cells from 6- to 8-week-old female BALB/c mice; CD4+CD45RBhi T cell-mediated chronic colitis)[1]
-
Dosage:5.0 mg/kg
-
Administration:i.c.; weekly; 5 doses
-
Result:Reduced colonic TNF-α mRNA and protein levels by >75%.
Reduced colonic levels of proinflammatory (IL-1β, IL-6), Th1 (IFN-γ, IL-12), and Th17 (IL-17, IL-23) cytokines.
Prevented progressive weight loss.
Reduced disease activity index (DAI) scores.
Eliminated macroscopic colonic inflammation.
Reduced colonic myeloperoxidase (MPO) activity to near-normal levels.
Normalized faecal α1-antitrypsin (AAT) levels.
Significantly improved histopathological scores.
Chemical Information
-
SMILES
[Mouse Tnf ASO]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Mouse Tnf ASO Related Classifications
HY-188018 Related Classifications
Powered by Bioz